MYDECINE
Revolutionizing Natures Medicine for Mental Health & Vitality
Mydecine Innovations Group Logo 2021
Revolutionizing Nature's Medicine
for Mental Health & Vitality

About Us


Mydecine Innovations Group™️ (NEO: MYCO) (OTC:MYCOF) (FSE:0NFA) is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing vitality. The company’s world-renowned medical and scientific advisory board is building out a robust R&D pipeline of nature-sourced psychedelic-assisted therapeutics, novel compounds, therapy protocols, and unique delivery systems. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, cultivate, extract/isolate, and analyze active mushroom compounds with full government approval through Health Canada. Mydecine also operates out of a state-of-the-art mycology lab in Denver, CO to focus on genetic research for scaling commercial cultivation of rare (non-psychedelic) medicinal mushrooms.

At the heart of Mydecine’s core philosophy is that Psychedelic-assisted psychotherapy will continue to gain acceptance in the medical community with many of the world’s best accredited research organizations demonstrating its remarkable clinical effectiveness. Mydecine recognizes the responsibility associated with psychedelic-assisted therapy and will continue to position itself as a long-term leader across the spectrum of clinical trials, research, technology, and global supply. 

Team leadership is key, The Scientific Advisory Board (“SAB”) that Mydecine has pulled together from its operational branches is enviable in the field of mental health solutions. Its current members are world-renowned medical and scientific professionals drawn from within academic, research and development, military, and corporate environments. As leaders in the field of PTSD, Mental Health including clinical practice, and advocacy, each member has made significant contributions to advancing the field and are committed to furthering Mydecine’s mission. The mandate of this SAB continues to provide strategic guidance and direction for Mydecine’s clinical trials for PTSD, underpinned by pure data research, therapy, and scientific programs, advise on intellectual property; and, contribute commentary on Mydecine’s telehealth platform, Mindleap Health™.  

Mydecine has also successfully completed multiple acquisitions since its inception.
View Acquisitions

Our Portfolio

Natural Health Products
Learn More→
We are discovering, extracting, and combining powerful fungtional© and psychedelic ingredients in mushrooms to balance and enhance the brain.
Research & Development
We are charting new paths with Neurological Disorder Medicines based on the novel compounds found in psychedelic medicines.
Learn More→
Learn More→Digital Health Solutions
We are developing breakthrough digital technologies to augment mental healthcare with data, digital therapeutics, and global connectivity.

Our Story

We started Mydecine Innovations Group™️ with the goal of revolutionizing the way people live and experience life by offering cutting edge natural products and technologies. Our international team has been described as a collection of passionate business leaders, scientists, mental health professionals and technology visionaries.

We are inspired by the future, the innovators, the dreamers; and our products embody this  spirit. They are built for those that aspire to be healthy physically and spiritually while living life to the fullest and daring to disrupt the norm.

Our passion sent us on a mission to develop high quality products and disruptive new technologies so we can contribute to making the world a better place.

For Investors

Ticker Symbols
NEO: MYCO
OTC: MYCOF
FSE: 0NFA
SEDAR ProfileInvestor Presentation
1d
5d
1m
6m
ytd
1y

Mydecine Innovations Group is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Mydecine Innovations Group's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Mydecine Innovations Group or its management. Mydecine Innovations Group does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Upcoming Events

H.C. Wainwright 23rdAnnual Global Investment Conference

September 13 - 15, 2021

Register Here

Oppenheimer FallHealthcare Life Sciences & MedTech Summit

September 20 - 23, 2021

Register Here

Maxim’s Advances in Mental Health Conference

Wednesday, September 22, 2021

Register Here

Analyst Coverage

See All News →

Mydecine Innovations Group Receives Shareholder and Court Approval for Spin-Out of Cannabis Subsidiaries

September 24, 2021
Mydecine shareholders voted 99.939% in favour of approving the Arrangement and received final approval of the Supreme Court of British Columbia.
Read More →

Mydecine Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data

September 22, 2021
Patent pending formulation has the potential to further reduce patient anxiety as compared to pure psilocybin, when used in therapy or medical practice.
Read More →

Mydecine Innovations Group Announces MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial

September 7, 2021
Dr. Matthew Johnson will lead research to look at the science and efficacy of MYCO-001 for the treatment of smoking cessation and nicotine dependence.
Read More →
News & Media
Text Link